LivaNova PLC — 2023 Q2 Form 10-Q Summary
Business context and reporting period
LivaNova is a global medical technology company with three reportable segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support (ACS). The unaudited filing covers the three and six months ended June 30, 2023, with comparative periods ended June 30, 2022. Financial statements are presented in U.S. dollars under U.S. GAAP.
Key developments included the U.S. commercial launch of the Essenz heart-lung machine, expanded European commercialization, continued progress in the RECOVER depression study, and the wind-down of the former heart failure program.
Key financial metrics
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Net revenue | $293.9 million | $254.2 million | $557.3 million | $494.3 million |
| Revenue growth | 15.6% | 12.7% | ||
| Gross profit | $205.2 million | $184.4 million | $379.3 million | $352.8 million |
| Gross margin | 69.8% | 72.5% | 68.1% | 71.4% |
| Operating income | $17.4 million | $31.8 million | $15.0 million | $41.3 million |
| Operating margin | 5.9% | 12.5% | 2.7% | 8.3% |
| Net income | $1.2 million | $16.4 million | $8.5 million | $19.4 million |
| Diluted EPS | $0.02 | $0.30 | $0.16 | $0.36 |
Six-month operating cash flow was $2.8 million, compared with $15.6 million in the prior-year period. Investing cash outflow was $18.1 million, including $13.3 million of capital expenditures and $5.4 million of investments. Financing cash inflow was $30.8 million, primarily reflecting the $50.0 million draw under the Delayed Draw Term Facility. Cash, cash equivalents and restricted cash totaled $534.4 million at June 30, 2023, including $311.4 million restricted as collateral for the SNIA Litigation Guarantee.
Cash and cash equivalents were $222.9 million. Total debt obligations were $587.0 million, comprising $19.1 million current debt and $568.0 million long-term debt. The Company had no borrowings under its $125.0 million revolving credit facility and reported compliance with its debt covenants.
Material changes versus the prior comparable period
- Revenue increased across Cardiopulmonary and Neuromodulation, while ACS revenue declined for the six-month period.
- Cardiopulmonary revenue increased 19.7% in Q2 and 16.4% year to date, driven by oxygenator demand and heart-lung machine placements. Segment income rose to $11.4 million in Q2 from $3.6 million.
- Neuromodulation revenue increased 13.1% in Q2 and 11.4% year to date, driven by new and replacement implants. Segment income declined 25.7% in Q2 and 26.7% year to date, primarily because of unfavorable changes in ImThera contingent consideration and higher clinical-study spending.
- ACS revenue increased 0.7% in Q2 but declined 8.4% year to date, reflecting fewer COVID-19-related ECMO patients and product mix. ACS reported a segment loss of $4.8 million in Q2 and $11.2 million year to date.
- Gross margin declined because of higher contingent consideration expense and supply-chain, labor, inflation, and logistics costs, partly offset by pricing actions, volume, and lower inbound freight costs.
- Research and development expense increased to $51.1 million in Q2 from $34.2 million, primarily reflecting contingent consideration and RECOVER and OSPREY clinical activities.
- Other operating expense increased to $10.8 million in Q2 from $1.9 million, largely due to additional 3T Heater-Cooler litigation provisions.
- Interest expense increased to $14.8 million in Q2 and $28.2 million year to date, reflecting higher average borrowings and interest rates.
- Foreign exchange and other income increased to $28.3 million year to date from $5.5 million, primarily due to fair-value changes in the exchangeable notes derivative, capped calls, foreign exchange, and interest income. This income was a significant contributor to reported pretax earnings.
Outlook, commentary, risks, and unusual items
Management stated that available liquidity, expected operating cash generation, and available revolving-credit capacity should be sufficient to fund operating needs, working capital, capital expenditures, acquisition earn-outs, and debt service over the twelve months following issuance of the financial statements. The filing does not provide a clear quantitative full-year revenue or earnings guidance figure.
- Macroeconomic risks include foreign-exchange volatility, inflation, supply-chain delays, labor shortages, higher freight and manufacturing costs, geopolitical instability, and potential effects from the Russia-Ukraine conflict.
- The Company recorded a $25.4 million 3T Heater-Cooler litigation provision at June 30, 2023 and was aware of approximately 80 filed and unfiled worldwide claims as of July 26, 2023. Management states that actual resolution costs may differ from the accrued amount.
- The SNIA environmental litigation remains a major contingency. LivaNova faces an Italian Court of Appeal damages order of approximately €453.6 million, while its appeal is pending. Payment is suspended subject to a €270.0 million first-demand bank guarantee backed by restricted cash. The Company expects the judicial process to be delayed until at least 2024.
- The estimated Saluggia hazardous-substances liability was €34.0 million, with an estimated loss range up to €43.3 million, at June 30, 2023.
- The Company accrued $7.4 million for the Italian medical-device payback matter. A separate Mitral warranty claim alleges damages exceeding €20.8 million, but the contractual cap is generally €8.0 million; no liability was recorded because a loss was not considered probable.
- The $287.5 million principal amount of 3.00% cash exchangeable senior notes matures in December 2025. The exchange condition was not satisfied for the quarter ended June 30, 2023.
- Level 3 derivative valuations remain sensitive to LivaNova’s share price and volatility. The embedded exchange-feature liability was $53.7 million and the capped-call asset was $42.0 million at June 30, 2023.
- Management concluded that disclosure controls and procedures were effective as of June 30, 2023, with no material changes in internal control over financial reporting.
Investor verification priorities
- Verify whether revenue growth and the Essenz launch translate into sustained Cardiopulmonary margin improvement.
- Monitor ACS losses, product demand, ECMO volumes, and the timing of any improvement in the business.
- Assess the sustainability of earnings excluding derivative fair-value gains and other non-operating items.
- Reconcile restricted cash, the SNIA litigation guarantee, and the potential liquidity impact of an adverse legal outcome.
- Track 3T Heater-Cooler claims, settlement payments, and changes in the $25.4 million litigation provision.
- Review refinancing or repayment plans for the exchangeable notes due in December 2025 and the floating-rate Term Facilities.
- Follow RECOVER and OSPREY clinical milestones, CMS reimbursement prospects, and related R&D spending.